Core Insights - The combination of KEYTRUDA and LENVIMA shows a durable 5-year survival benefit compared to chemotherapy for patients with advanced endometrial carcinoma [1] Group 1 - KEYTRUDA plus LENVIMA demonstrates significant efficacy in improving survival rates for patients suffering from advanced endometrial carcinoma [1] - The study highlights the long-term benefits of this combination therapy over traditional chemotherapy options [1]

Core Insights - Merck is set to present new research at the ESMO Congress 2025, showcasing over 100 abstracts across more than 20 cancer types, highlighting its commitment to advancing cancer treatment outcomes [1][2]. Group 1: Existing Medicines - Key data on existing medicines in Merck's portfolio will be presented, including findings for KEYTRUDA, LENVIMA, WELIREG, and KEYTRUDA QLEX [2][3]. - Research on KEYTRUDA's impact in bladder, ovarian, and lung cancers will be featured in three Presidential Symposium presentations [2]. Group 2: Investigational Candidates - New data for investigational antibody-drug conjugates (ADCs) will be presented, including raludotatug deruxtecan and ifinatamab deruxtecan, both discovered by Daiichi Sankyo [4]. - Research on sacituzumab tirumotecan, a TROP2-directed ADC, will be shared in four presentations focusing on lung, breast, cervical, and prostate cancers [4]. Group 3: Key Studies - First-time data from the Phase 3 KEYNOTE-905/EV-303 study evaluating KEYTRUDA plus Padcev for muscle-invasive bladder cancer will be presented [6]. - Five-year exploratory follow-up data from the Phase 3 KEYNOTE-775/Study 309 trial evaluating KEYTRUDA plus LENVIMA for advanced endometrial cancer will be showcased [6]. - Ten-year follow-up data from trials evaluating KEYTRUDA monotherapy for metastatic non-small cell lung cancer (NSCLC) will be presented [6]. Group 4: Clinical Research Program - Merck has the largest immuno-oncology clinical research program in the industry, with over 1,600 trials studying KEYTRUDA across various cancers and treatment settings [8].